Literature DB >> 29797382

Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics.

S M P Bennet1,2, O Palsson3, W E Whitehead3, D A Barrow4, H Törnblom1, L Öhman1,2, M Simrén1,3, M A L van Tilburg3,5,6.   

Abstract

BACKGROUND: Serum levels of pro-inflammatory cytokines tend to be increased in irritable bowel syndrome (IBS) patients, or subgroups thereof. Still, the link between cytokine levels and IBS symptoms is unclear. We aim to determine systemic cytokine levels in IBS patients and healthy subjects (HS), confirm the presence of a subset of patients with an increased immune activity and to establish if cytokines are linked to IBS symptoms and pathophysiological factors.
METHODS: Serum levels of interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF), and IL-10 were measured. All subjects reported IBS symptoms using validated questionnaires and underwent colonic sensorimotor testing. Multivariate supervised orthogonal partial least squares-discriminant analysis (OPLS-DA) and unsupervised principal component analysis (PCA) and hierarchical cluster analysis (HCA) were implemented. KEY
RESULTS: Irritable bowel syndrome patients (n = 246) had higher serum levels of IL-1β, IL-6, IL-8, TNF, and IL-10 compared to HS (n = 21); however, serum cytokine profiles could not discriminate patients from HS. Moreover, cytokine levels were not correlated with symptoms among patients. Supervised OPLS-DA identified 104 patients (40% of patients) and unsupervised HCA analysis identified 49 patients (20%) with an increased immune activity indicated by elevated levels of serum cytokines compared to HS and the other patients. However, irrespective of how patients with increased immune activity were identified they were symptomatically similar to patients with no indication of increased immune activity. CONCLUSIONS & INFERENCES: Serum cytokines are elevated in IBS patients compared to HS. Immune activation characterizes a subset of patients, but modest associations between cytokine profile and symptoms suggest immune activity does not directly influence symptoms in IBS.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  IBS; cytokines; symptom

Mesh:

Substances:

Year:  2018        PMID: 29797382     DOI: 10.1111/nmo.13378

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  5 in total

Review 1.  The Role of Inflammatory Mediators in the Development of Gastrointestinal Motility Disorders.

Authors:  Tibor Docsa; Adám Sipos; Charles S Cox; Karen Uray
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

2.  Activation of Peripheral Blood CD4+ T-Cells in IBS is not Associated with Gastrointestinal or Psychological Symptoms.

Authors:  Yasmin Nasser; Carlene Petes; Celine Simmers; Lilian Basso; Christophe Altier; Katrina Gee; Stephen J Vanner
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

3.  Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use.

Authors:  Kendra J Kamp; Claire Han; Robert J Shulman; Kevin C Cain; Pamela Barney; Mark R Opp; Lin Chang; Robert L Burr; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2020-07-17       Impact factor: 2.522

4.  Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms.

Authors:  Luiza Moraes; Maria K Magnusson; Georgios Mavroudis; Annikka Polster; Börje Jonefjäll; Hans Törnblom; Johanna Sundin; Magnus Simrén; Hans Strid; Lena Öhman
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

Review 5.  Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis.

Authors:  Caterina Carco; Wayne Young; Richard B Gearry; Nicholas J Talley; Warren C McNabb; Nicole C Roy
Journal:  Front Cell Infect Microbiol       Date:  2020-09-09       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.